Kyntra Bio Q2 FY26 returns to profit at $12 million; revenue turns to $(1.5) million
Reuters2026/08/13 20:04- Kyntra Bio posted Q2 revenue of $(1.47) million, swinging from $1.35 million a year earlier.
- Net income from continuing operations turned to $12 million, or $2.96 per share, from a $13.7 million loss.
- Operating loss widened to $17.57 million from $12.05 million, while interest and other income rose to $29.55 million on a $30.94 million gain.
- Cash, cash equivalents, investments, and accounts receivable totaled $95.7 million at June 30; funding runway projected into 2028.
- FG-3246 Phase 2 enrollment continued with interim analysis slated for 4Q 2026; roxadustat Phase 3 in LR-MDS targeted to start 4Q 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
